Follow
NEERAJ Agarwal
NEERAJ Agarwal
Verified email at hci.utah.edu
Title
Cited by
Cited by
Year
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
NM Kuderer, TK Choueiri, DP Shah, Y Shyr, SM Rubinstein, DR Rivera, ...
The Lancet 395 (10241), 1907-1918, 2020
18462020
Olaparib for metastatic castration-resistant prostate cancer
J de Bono, J Mateo, K Fizazi, F Saad, N Shore, S Sandhu, KN Chi, ...
New England Journal of Medicine 382 (22), 2091-2102, 2020
17052020
Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a …
ED Kwon, CG Drake, HI Scher, K Fizazi, A Bossi, AJM Van den Eertwegh, ...
The lancet oncology 15 (7), 700-712, 2014
15702014
Apalutamide for metastatic, castration-sensitive prostate cancer
KN Chi, N Agarwal, A Bjartell, BH Chung, AJ Pereira de Santana Gomes, ...
New England Journal of Medicine 381 (1), 13-24, 2019
12392019
Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial
TK Choueiri, B Escudier, T Powles, NM Tannir, PN Mainwaring, BI Rini, ...
The lancet oncology 17 (7), 917-927, 2016
10452016
External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study
DYC Heng, W Xie, MM Regan, LC Harshman, GA Bjarnason, ...
The lancet oncology 14 (2), 141-148, 2013
10392013
Survival with olaparib in metastatic castration-resistant prostate cancer
M Hussain, J Mateo, K Fizazi, F Saad, N Shore, S Sandhu, KN Chi, ...
New England Journal of Medicine 383 (24), 2345-2357, 2020
5792020
Kidney cancer, version 2.2017, NCCN clinical practice guidelines in oncology
RJ Motzer, E Jonasch, N Agarwal, S Bhayani, WP Bro, SS Chang, ...
Journal of the National Comprehensive Cancer Network 15 (6), 804-834, 2017
5632017
Bladder cancer, version 3.2020, NCCN clinical practice guidelines in oncology
TW Flaig, PE Spiess, N Agarwal, R Bangs, SA Boorjian, ...
Journal of the National Comprehensive Cancer Network 18 (3), 329-354, 2020
5212020
Cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium
DYC Heng, JC Wells, BI Rini, B Beuselinck, JL Lee, JJ Knox, ...
European urology 66 (4), 704-710, 2014
5062014
Kidney cancer
RJ Motzer, N Agarwal, C Beard, GB Bolger, B Boston, MA Carducci, ...
Journal of the National Comprehensive Cancer Network 7 (6), 618-630, 2009
4282009
Advances in bladder cancer biology and therapy
L Tran, JF Xiao, N Agarwal, JE Duex, D Theodorescu
Nature Reviews Cancer 21 (2), 104-121, 2021
4252021
Bladder cancer
PE Clark, N Agarwal, MC Biagioli, MA Eisenberger, RE Greenberg, ...
Journal of the National Comprehensive Cancer Network 11 (4), 446-475, 2013
4122013
Kidney cancer, version 3.2022, NCCN clinical practice guidelines in oncology
RJ Motzer, E Jonasch, N Agarwal, A Alva, M Baine, K Beckermann, ...
Journal of the National Comprehensive Cancer Network 20 (1), 71-90, 2022
3692022
The International Metastatic Renal Cell Carcinoma Database Consortium model as a prognostic tool in patients with metastatic renal cell carcinoma previously treated with first …
JJ Ko, W Xie, N Kroeger, J Lee, BI Rini, JJ Knox, GA Bjarnason, S Srinivas, ...
The lancet oncology 16 (3), 293-300, 2015
3682015
Enzalutamide versus bicalutamide in castration-resistant prostate cancer: the STRIVE trial
DF Penson, AJ Armstrong, R Concepcion, N Agarwal, C Olsson, L Karsh, ...
Journal of Clinical Oncology 34 (18), 2098-2106, 2016
3602016
TROPHY-U-01: a phase II open-label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma progressing after platinum-based chemotherapy and checkpoint …
ST Tagawa, AV Balar, DP Petrylak, AR Kalebasty, Y Loriot, A Fléchon, ...
Journal of Clinical Oncology 39 (22), 2474, 2021
3512021
Circulating tumor cell counts are prognostic of overall survival in SWOG S0421: a phase III trial of docetaxel with or without atrasentan for metastatic castration-resistant …
A Goldkorn, B Ely, DI Quinn, CM Tangen, LM Fink, T Xu, P Twardowski, ...
Journal of clinical oncology 32 (11), 1136, 2014
3302014
Apalutamide in patients with metastatic castration-sensitive prostate cancer: final survival analysis of the randomized, double-blind, phase III TITAN study
KN Chi, S Chowdhury, A Bjartell, BH Chung, ...
Journal of Clinical Oncology 39 (20), 2294-2303, 2021
3212021
Randomized phase II trial of sunitinib on an intermittent versus continuous dosing schedule as first-line therapy for advanced renal cell carcinoma
RJ Motzer, TE Hutson, MR Olsen, GR Hudes, JM Burke, WJ Edenfield, ...
J Clin Oncol 30 (12), 1371-1377, 2012
3052012
The system can't perform the operation now. Try again later.
Articles 1–20